Abstract
Background: Pharmacoresistant epilepsy is a disabling neuronal disorder with harmful consequences that impact patient’s quality of life. Although psychiatric comorbidities are frequently present in patients with epilepsy, they are more common in those patients with pharmacoresistant epilepsy. Despite medical advances, the current existing therapeutic strategies for pharmacoresistant seizure control are not available for all patients and/or present disadvantages. Moreover, the conventional drug therapies for psychiatric comorbidities have several adverse effects. Therefore, in this field, nanotechnology arises as a novel tool for transporting drugs to the brain under pathological conditions with high efficiency and low side effects.
Objective: Present an overview of nanotechnology as a novel, efficient and enhanced therapeutic strategy for controlling pharmacoresistant epilepsy and its associated psychiatric comorbidities.
Conclusion: Nanotechnology emerges as a powerful tool for the control and/or treatment of pharmacoresistant epilepsy and its comorbidities in a more efficient and safer way than conventional treatments.
Keywords: Nanotechnology, Pharmacorresistant epilepsy, Psychiatric comorbidity, Seizures, Side effects.
Mini-Reviews in Medicinal Chemistry
Title:Nanotechnology as Potential Strategy for the Treatment of Pharmacoresistant Epilepsy and Comorbid Psychiatric Disorders
Volume: 17 Issue: 3
Author(s): Argelia Rosillo-de la Torre, Luisa Rocha, Hermelinda Salgado-Ceballos, Perla E. García Casillas and Gabriel Luna-Barcenas
Affiliation:
Keywords: Nanotechnology, Pharmacorresistant epilepsy, Psychiatric comorbidity, Seizures, Side effects.
Abstract: Background: Pharmacoresistant epilepsy is a disabling neuronal disorder with harmful consequences that impact patient’s quality of life. Although psychiatric comorbidities are frequently present in patients with epilepsy, they are more common in those patients with pharmacoresistant epilepsy. Despite medical advances, the current existing therapeutic strategies for pharmacoresistant seizure control are not available for all patients and/or present disadvantages. Moreover, the conventional drug therapies for psychiatric comorbidities have several adverse effects. Therefore, in this field, nanotechnology arises as a novel tool for transporting drugs to the brain under pathological conditions with high efficiency and low side effects.
Objective: Present an overview of nanotechnology as a novel, efficient and enhanced therapeutic strategy for controlling pharmacoresistant epilepsy and its associated psychiatric comorbidities.
Conclusion: Nanotechnology emerges as a powerful tool for the control and/or treatment of pharmacoresistant epilepsy and its comorbidities in a more efficient and safer way than conventional treatments.
Export Options
About this article
Cite this article as:
la Torre Rosillo-de Argelia, Rocha Luisa, Salgado-Ceballos Hermelinda, García Casillas E. Perla and Luna-Barcenas Gabriel, Nanotechnology as Potential Strategy for the Treatment of Pharmacoresistant Epilepsy and Comorbid Psychiatric Disorders, Mini-Reviews in Medicinal Chemistry 2017; 17 (3) . https://dx.doi.org/10.2174/1389557516666161013105000
DOI https://dx.doi.org/10.2174/1389557516666161013105000 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Mitochondria as a Therapeutic Target in Metabolic Disorders
Mitochondria are the primary site of adenosine triphosphate (ATP) production in mammalian cells. Moreover, these organelles are an important source of reactive oxygen and nitrogen species in virtually any nucleated cell type. The modulation of a myriad of cellular signaling pathways depends on the mitochondrial physiology. Mitochondrial dysfunction is observed ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Synthesis and Anticonvulsant Activity of N-(trans)- 3-phenylprop-2-en-1-yl (Cinnamyl) Derivatives of Aminoalkanols
Letters in Drug Design & Discovery Sestrins: A New Kid for Stroke Treatment?
Current Drug Delivery Bacterial Protein Toxins: Current and Potential Clinical Use
Current Medicinal Chemistry Neurogenic Drugs and Compounds to Treat CNS Diseases and Disorders
Central Nervous System Agents in Medicinal Chemistry Diabetes, Cognitive Function, and the Blood-Brain Barrier
Current Pharmaceutical Design Polycystic Ovary Syndrome as a Proinflammatory State: The Role of Adipokines
Current Pharmaceutical Design Recombinant Expression, Functional Characterization of Two Scorpion Venom Toxins with Three Disulfide Bridges from the Chinese Scorpion Buthus martensii Karsch
Protein & Peptide Letters Editorial [Hot Topic: Membrane Channels as Therapeutic Targets (Executive Editor: Jean-Claude Herve)]
Current Pharmaceutical Design Topiramate: Its Pharmacological Properties and Therapeutic Efficacy in Epilepsy
Mini-Reviews in Medicinal Chemistry Current Prodrug Design for Drug Discovery
Current Pharmaceutical Design White Matter Damage Along the Uncinate Fasciculus Contributes to Cognitive Decline in AD and DLB
Current Alzheimer Research Prospective Role of Polyphenolic Compounds in the Treatment of Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Recent Advances on Neural Tube Defects with Special Reference to Valproic Acid
Endocrine, Metabolic & Immune Disorders - Drug Targets Inhalational Anesthetic Sevoflurane Rescues Retina Function in Alzheimer’s Disease Transgenic Drosophila
Current Alzheimer Research PET Imaging of Opioid Receptors in Pain: Progress and New Directions
Current Pharmaceutical Design Neuropsychiatric and General Interactions of Natural and Synthetic Cannabinoids with Drugs of Abuse and Medicines
CNS & Neurological Disorders - Drug Targets Could Hippocampal Neurogenesis be a Future Drug Target for Treating Temporal Lobe Epilepsy?
CNS & Neurological Disorders - Drug Targets Coumarin-1,2,3-triazole Hybrid Molecules: An Emerging Scaffold for Combating Drug Resistance
Current Topics in Medicinal Chemistry Applications of Nanocarbons in Bio-Medical Devices
Recent Innovations in Chemical Engineering MtDNA As a Cancer Marker: A Finally Closed Chapter?
Current Genomics